TY - JOUR
T1 - The Nlrp3 Inflammasome Does Not Regulate Alloimmunization to Transfused Red Blood Cells in Mice
AU - Gibb, David R.
AU - Calabro, Samuele
AU - Liu, Dong
AU - Tormey, Christopher A.
AU - Spitalnik, Steven L.
AU - Zimring, James C.
AU - Hendrickson, Jeanne E.
AU - Hod, Eldad A.
AU - Eisenbarth, Stephanie C.
N1 - Funding Information:
We would like to thank M. Firla for technical assistance. This work was supported by the National Blood Foundation (S.C.E) and the American Society of Hematology (S.C.E). Funders had no role in study design, data collection, data analysis, interpretation or writing of the report.
Publisher Copyright:
© 2016 The Authors
PY - 2016
Y1 - 2016
N2 - Red blood cell (RBC) transfusions are essential for patients with hematological disorders and bone marrow failure syndromes. Despite ABO matching, RBC transfusions can lead to production of alloantibodies against “minor” blood group antigens. Non-ABO alloimmunization is a leading cause of transfusion-associated mortality in the U.S. Despite its clinical importance, little is known about the immunological factors that promote alloimmunization. Prior studies indicate that inflammatory conditions place patients at higher risk for alloimmunization. Additionally, co-exposure to pro-inflammatory pathogen associated molecular patterns (PAMPs) promotes alloimmunization in animal models, suggesting that RBC alloimmunization depends on innate immune cell activation. However, the specific innate immune stimuli and sensors that induce a T cell-dependent alloantibody response to transfused RBCs have not been identified. The NLRP3 inflammasome senses chemically diverse PAMPs and damage associated molecular patterns (DAMPs), including extracellular ATP and iron-containing heme. We hypothesized that activation of the NLRP3 inflammasome by endogenous DAMPs from RBCs promotes the alloimmune response to a sterile RBC transfusion. Using genetically modified mice lacking either NLRP3 or multiple downstream inflammasome response elements, we ruled out a role for the NLRP3 inflammasome or any Caspase-1 or -11 dependent inflammasome in regulating RBC alloantibody production to a model antigen.
AB - Red blood cell (RBC) transfusions are essential for patients with hematological disorders and bone marrow failure syndromes. Despite ABO matching, RBC transfusions can lead to production of alloantibodies against “minor” blood group antigens. Non-ABO alloimmunization is a leading cause of transfusion-associated mortality in the U.S. Despite its clinical importance, little is known about the immunological factors that promote alloimmunization. Prior studies indicate that inflammatory conditions place patients at higher risk for alloimmunization. Additionally, co-exposure to pro-inflammatory pathogen associated molecular patterns (PAMPs) promotes alloimmunization in animal models, suggesting that RBC alloimmunization depends on innate immune cell activation. However, the specific innate immune stimuli and sensors that induce a T cell-dependent alloantibody response to transfused RBCs have not been identified. The NLRP3 inflammasome senses chemically diverse PAMPs and damage associated molecular patterns (DAMPs), including extracellular ATP and iron-containing heme. We hypothesized that activation of the NLRP3 inflammasome by endogenous DAMPs from RBCs promotes the alloimmune response to a sterile RBC transfusion. Using genetically modified mice lacking either NLRP3 or multiple downstream inflammasome response elements, we ruled out a role for the NLRP3 inflammasome or any Caspase-1 or -11 dependent inflammasome in regulating RBC alloantibody production to a model antigen.
KW - Alloimmunization
KW - Conventional dendritic cells (cDCs)
KW - Inflammasome
KW - NLRP3
KW - Red blood cell (RBC) storage
UR - http://www.scopus.com/inward/record.url?scp=84991666190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991666190&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2016.06.008
DO - 10.1016/j.ebiom.2016.06.008
M3 - Article
C2 - 27345021
AN - SCOPUS:84991666190
SN - 2352-3964
VL - 9
SP - 77
EP - 86
JO - EBioMedicine
JF - EBioMedicine
ER -